The FDA has extended its review of the ProSense cryoablation system for early-stage breast cancer, with a decision expected ...

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive ...

The trial, being conducted under an investigational device exemption (IDE) from the Food and Drug Administration (FDA), is evaluating the safety and effectiveness of the Adagio VT cryoablation system ...

"IceCure reports full tumour reduction after six months in cryoablation study" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this ...

IceCure Medical Ltd’s ICCM share price has dipped by 15.54%, which has investors questioning if this is right time to buy.

A study led by UCLA investigators shows that artificial intelligence (AI) could play a key role in improving treatment outcomes for men with prostate cancer by helping physicians determine who is most ...

IceCure Medical has sought approval from Israel's Ministry of Health’s Medical Device Division (AMAR) for its XSense cryoablation system and cryoprobes. Both components have already gained ...

Background: Cryoablation (CRYO) is an alternative to radiofrequency (RF) ablation in the treatment of atrioventricular nodal reentrant tachycardia (AVNRT). This study aims to evaluate the ...

today announced it has filed for regulatory approval with the Medical Device Division ("AMAR") of Israel's Ministry of Health for its next-generation single cryoprobe cryoablation system ...